|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 冠状动脉内影像学临床应用专家共识(第一部分):对冠状动脉介入治疗的指导与优化显示文摘欧洲心血管介入协会(EAPCI)专家组系统总结了血管内超声(IVUS)和光学相干断层成像(OCT)这两种血管内影像学检查临床应用指征的现有证据,提供了关于IVUS和OCT指导经皮冠状动脉介入治疗(PCI)的应用价值,并明确了最可能从腔内影像学指导的介入治疗中获得临床收益的患者或病变类型,同时详细论述了PCI前如何使用IVUS或OCT优化支架尺寸(支架长度和直径)和手术策略的选择。此外,专家推荐对支架失败(支架内再狭窄或支架内血栓形成)的患者应常规进行冠状动脉内影像学检查,并首选OCT。最后,重点论述了IVUS和OCT在指导PCI和评估支架失败两个方面的优势和局限性,并对未来需要深入研究的领域进行了展望。 | Lorenz Raber Gary S Mintz Konstantinos C Koskinas Thomas W Johnson Niels R Holm Yoshinubo Onuma Maria D Radu Michael Joner Bo Yu Haibo Jia Nicolas Meneveau Jose M.de la Torre Hemandez Javier Escaned Jonathan Hill Francesco Prati Antonio Colombo Carlo di Mario Evelyn Regar Davide Capodanno William Wijns Robert A Byme Giulio Guagliumi | 2019 | 中华心血管病杂志2019，47，1： | 17 |
| 2 | 面中部牵引成骨术矫正综合征性面中部后缩畸形显示文摘目的 探讨牵引成骨术治疗面中部后缩畸形的可行性。方法 2 0 0 1至 2 0 0 2年对 4例Crouzon、Apert和Marfan综合征 ,并伴面中部后缩畸形的患者 ,分别行LeFortIII内置式延长器 (2例 )、LeFortIII水平外置式延长器 (1例 )、monobloc水平内置式延长器 (1例 )治疗 ,于截骨后 4d开始牵引延长 ,速度为每天 1mm。结果 按计划完成牵引 ,面中部前移 8~ 2 0mm。面中部后缩畸形明显减轻 ,双侧对称 ,尤其眶、鼻根部效果更佳 ,随访 4个月至 1年 ,效果稳定。结论 骨牵引成骨术具有传统的植骨加坚强内固定的方法所无法比拟的优点 ,能较大范围前移面中部 ,是矫正各种发育不良造成的严重面中部后缩畸形的有效而可行的方法。 | 滕利 Andrew A Heggie Anthony D Holmes | 2005 | 中华整形外科杂志2005，21，1： | 8 |
| 3 | Efficacy and safety of tenofovir in chronic hepatitis B: Australian real world experience显示文摘AIM To evaluate the long-term treatment outcomes of tenofovir therapy in patients in a real world Australian tertiary care setting.METHODS We performed a retrospective analysis of treatment outcomes among treatment-na?ve and treatment-experienced patients receiving a minimum 3 mo tenofovir therapy through St Vincent's Hospital Melbourne, Australia. We included patients receiving tenofovir [tenofovir disoproxil fumarate(TDF)] monotherapy, as well as patients treated with TDF in combination with a second antiviral agent. Patients were excluded if they demonstrated human immune-deficiency virus/hepatitis C virus/hepatitis delta virus coinfection or were less than 18 years of age. We considered virological and biochemicalresponse, as well as safety outcomes. Virological response was determined by measurement of hepatitis B virus(HBV) DNA using sensitive assays; biochemical response was determined via serum liver function tests; histological response was determined from liver biopsy and fibroscan; safety analysis focused on glomerular renal function and bone mineral density. The primary efficacy endpoint was complete virological suppression over time, defined by HBV DNA < 20 IU/m L. Secondary efficacy endpoints included rates of biochemical response, and HB e antigen(HBe Ag)/HB surface antigen loss and seroconversion over time.RESULTS Ninety-two patients were identified who fulfilled the enrolment criteria. Median follow-up was 26 mo(range 3-114). Mean age was 46(24-78) years, 64(70%) were male and 77(84%) were of Asian origin. 55(60%) patients were treatment-na?ve and 62 patients(67%) were HBe Ag-negative. Complete virological suppression was achieved by 45/65(71%) patients at 12 mo, 37/46(80%) at 24 mo and 25/28(89%) at 36 mo. Partial virological response(HBV DNA 20-2000 IU/m L) was achieved by 89/92(96.7%) of patients. Multivariate analysis showed a significant relationship between virological suppression at end of follow-up and baseline HBV DNA level(OR = 0.897, 95%CI: 0.833-0.967, P = 0.0046) and HBe Ag positive status(OR = 0.373, 95%CI: 0.183-0.762, P = 0.0069). There was no difference in response comparing treatment-na?ve and treatment-experienced patients. Three episodes of virological breakthrough occurred in the setting of noncompliance. Tenofovir therapy was well tolerated.CONCLUSION Tenofovir is an efficacious, safe and well-tolerated treatment in an Australian real-world tertiary care setting. Our data are similar to the reported experience from registration trials. | Grace C Lovett Tin Nguyen David M Iser Jacinta A Holmes Robert Chen Barbara Demediuk Gideon Shaw Sally J Bell Paul V Desmond Alexander J Thompson | 2017 | World Journal of Hepatology2017，9，1： | 7 |
| 4 | 针对患者利益的机器学习和人工智能研究:在透明性、可重复性、伦理和有效性等方面的20个关键问题显示文摘机器学习(ML)、人工智能(AI)和其他现代统计方法正为利用先前尚未开发且极速增长的数据资源提供新的机会,以期让患者获益。尽管目前正在进行许多有前景的研究,特别是在图像方面,但就文献整体而言还缺乏透明度、对可重复性清晰的阐述、对潜在伦理问题的探究,以及对有效性的明确验证。这些问题的存在有许多原因,其中最重要的一点(为此我们提供了初步解决方案)就是当前缺乏针对ML和AI的最佳实践指南。我们认为从事研究的跨学科团队和应用ML/AI影响健康的项目,将因解决有关透明度、可重复性、伦理和有效性(TREE)的一系列问题而受益。这里提出的20个关键问题为研究团队提供了一个研究设计、实施和报告框架;帮助编辑和同行评审专家评估文献的贡献;让患者、临床医生和政策制定者评估新发现可能会给患者带来的获益。 | Sebastian Vollmer Bilal A Mateen Gergo Bohner Franz J Kirdly Rayid Ghani Pall Jonsson Sarah Cumbers Adrian Jonas Katherine S L McAllister Puja Myles David Granger Mark Birse Richard Branson Karel G M Moons Gary S Collins John P A Chris Holmes Harry Hemingwayp 李峰(译) 徐磊(校) 赵邑(校) | 2020 | 英国医学杂志中文版2020，23，9： | 5 |
| 5 | 心房颤动——当今面临的挑战显示文摘在过去数年里,临床和科撞方面对心房颤动(房颤)的关注明显增加,有关这一论题的出版物数量迅速、稳定的增长就是证明。虽然已有一些新方法治疗遮一心律失常一但大多数房颤患者仍然不得不忍受这一心律失常,包括其不良后果和症状,房颤无疑是虽迫切需要有更好治疗方法的一种心律失常。为了达到这一目的,就需要更深刻地认识房颤的机制.以便开发直接影响这一基础病理生理机制的治疗措施。 | Olsson SB Hansson A Hedin E Holm M Ingemansson M Johansson R Meurling C Pehrson S Roijer A Yuan S 方丕华 | 1997 | 中华心律失常学杂志1997，1，1： | 3 |
| 6 | Electroluminescence in conjugated polymers 显示文摘 | FRIEND R H GYMER R W HOLMES A B | 1999 | Nature1999，397，： | 2 |
| 7 | IL 28 B genotype is not useful for predicting treatment outcome in A sian chronic hepatitis B patients treated with pegylated interferon‐α显示文摘 | Jacinta A Holmes Tin Nguyen Dilip Ratnam Neel M Heerasing Jane V Tehan Sara Bonanzinga Anouk Dev Sally Bell Stephen Pianko Robert Chen Kumar Visvanathan Rachel Hammond David Iser Ferry Rusli William Sievert Paul V Desmond D Scott Bowden Alexander J Thomps | 2013 | J Gastroenterol Hepatol2013，，5： | 2 |
| 8 | Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial显示文摘 | Friedrich W Mohr Marie-Claude Morice A Pieter Kappetein Ted E Feldman Elisabeth St?hle Antonio Colombo Michael J Mack David R Holmes Marie-angèle Morel Nic Van Dyck Vicki M Houle Keith D Dawkins Patrick W Serruys | 2013 | The Lancet . 2013 (9867)2013，，9867： | 2 |
| 9 | A Unified Approach to Clenshaw Summation and the Recursive Computation of Very High Degree and Order Normalized Associated Legendre Functions显示文摘 | Holmes S A Featherstone W E | 2002 | Journal of Geodesy2002，76，： | 1 |
| 10 | Implementation of a controlled rectifier using AC - AC matrix converter theory显示文摘 | HOLMES D J LIPO T A | 1992 | IEEE Power Electronics1992，7，1： | 1 |
| 11 | Galanin as a modulator of anxiety and depression and a therapeutic target for affective disease显示文摘 | Karlsson RM Holmes A | 2006 | Amino Acids2006，31，3： | 1 |
| 12 | Thermophily in the Geobacteraceae: Geotherrnobacter ehrlichii gen nov, sp nov, a novel thermophilic member of the Geobacteraceae from the 'Bag City' hydrothermal vent显示文摘 | Kashefi K Holmes D E Baross J A | 2003 | Applied and Environmental Microbiology2003，69，： | 1 |
| 13 | Comparison of to tal oral bioavailability and the lymphatic transport of halofantrine from three different unsaturated triglycerides in lymph-cannulated conscious rats 显示文摘 | Holm R Mtillertz A Christensen E | 2001 | Eur J Pharm Sci2001，14，4： | 1 |
| 14 | ChitosanN-sulfate,A watersoluble polyelectrolyte 显示文摘 | Holme K R Perlin A | 1997 | Carbohydrate Research1997，302，： | 1 |
| 15 | 显示文摘 | Grudowski P A Holmes A L Eiting C | 1996 | Appl Phys Lett1996，69，： | 1 |
| 16 | p53, p21 and mdm2 expression vs the response to radiotherapy in transitional cell carcinoma of the bladder显示文摘 | Rotterud R Berner A Holm R | 2001 | BJU Int2001，88，3： | 1 |
| 17 | Surigical treatment of intractable right sided infective endocarditis in drug addicts 25 years experience显示文摘 | Arbulu A Holmes RJ Asafaw I | 1993 | J Heart Valve Dis1993，2，2： | 1 |
| 18 | Analysis and simulation of a synthetic-aperture technique for imaging through a turbulent medium 显示文摘 | R B Holmes S Ma A Bhowmik | 1996 | J Opt SocAm A1996，13，2： | 1 |
| 19 | Effect of stress on gas permeability in concrete 显示文摘 | Sugiyama T Bremner T W Holm T A | 1996 | ACI Materials Journal1996，93，5： | 1 |
| 20 | The E75 HER2/neu peptide vaccine 显示文摘 | Mittendorf E A Holmes J P Ponniah S | 2008 | Cancer Immunol lmmu- nother2008，57，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员